Symmetrical triangle breakout seems in daily concentrate if price sustain above 252 in daily
this correction start 5 april 2022 this time price 47 and price go down 5 wave and price go up corrective wave b 12 may 2022 to 7 june 2022 and again price go down 5 wave structure this correction extended zig zag correction zig zag correction (5-3-5) zig zag correction price go down 5 wave and again move up a,b,c and down fall 5 wave this structure complete...
The stock is Completely in Bear Market as Impulse structure , its also Going to Make move up as Counter move as per forecast made on chart which can be easy trade as it will be fast by time One can look to enter with their own Method and Exit at $82 ( Preferred) Good luck
The stock can give a good upmove on crossing the resistance it is testing now. Supports marked in green. Resistance marked in red
$IBO over the years have maintained a solid and supple market cap, currently the company’s market capitalization is valued over $7.57M and is mounting effectively and the shares are actively being traded on OTC at $0.0376 per unit.
$IBO over the years have maintained a solid and supple market cap, currently the company’s market capitalization is valued over $7.57M and is mounting effectively
Universal Ibogaine Inc. is a Canadian Life science Company trading at OTC with ticker symbol $IBOGF currently sits at $0.0376 with volume around 10K+.
Universal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of $7K in the last 3 months. The average volume of the company in the last 10 days is $5.02K with $190.74M share outstanding. The stock price when the market opened was $0.0397.
Nasdaq moving as per the Downward trendline. falling trending line meeting at below 10k lets hope 8800 never comes and it take support at 10500 for reversal play.
Hemostemix is a publicly traded biotechnology company listed on OTC. Today it has recorded a market opening price of $0.2151.
$HMTXF today marked quite an impressive opening in the otc market and is currently trading with a steady pace at $0.1960 with a notable spike Hemostemix hires new financial advisor to the family Mr. Rick Groome who has effectively settled 2 securities firm, helping many successful biotechnology companies in providing funds over the last three decades has...
Universal Ibogaine Inc. holds a significant position over the OTC market with its greater difference between the lower and higher ranges of trading, which is $0.0258-$0.1143 in the last 52 weeks.
Neuropathic pain syndromes can be treated with NCP-01 and its autologous stem cell technology, which can treat disorders of the central and peripheral nervous systems. Spinal cord injury, chronic brainstem injury, traumatic brain injury, and peripheral nerve injury are all examples of traumatic injuries and many more
Disclaimer: I don’t own shares of UBER. The below analysis is not a trading or investment recommendation & is only for learning purpose. • Price is under the short term 20 period & long term 200 period moving averages. • Price & RSI show an unconfirmed bullish divergence. Confirmation of this divergence is obtained through price closing above the ...
UI is a life sciences industry on a mission to show the safety and efficacy of its ibogaine-based drug detox procedure in a planned Canadian Clinical Trial, with the goal of eventually licensing the protocol around the world.
Under the ticker symbol "JC4", UI's common shares have been registered for trade on the Frankfurt Stock Exchange, or Bourse Frankfurt. In Canada, UI will continue trading under the ticker name IBO on the TSX Venture Exchange and on the OTCQB under the ticker symbol IBOGF on the OTCQB
$IBO stock ticker to Universal Ibogaine a company that provides ibogaine addiction treatment to patients tormented from opioid addiction in Canada is currently trading swiftly at $0.03734 with an evident hike.
Blue Digital will be paid USD 27,000 for a three-month commitment beginning June 13, 2022. Additionally, Blue Digital will get 450,000 company's stock options to purchase common shares of the Company, with an exercise price of $0.10 per share, a three-year term, and one-third vesting at the conclusion of each month of service.